JP6300287B2 - インスリン産生膵島細胞移植用製剤 - Google Patents
インスリン産生膵島細胞移植用製剤 Download PDFInfo
- Publication number
- JP6300287B2 JP6300287B2 JP2016513798A JP2016513798A JP6300287B2 JP 6300287 B2 JP6300287 B2 JP 6300287B2 JP 2016513798 A JP2016513798 A JP 2016513798A JP 2016513798 A JP2016513798 A JP 2016513798A JP 6300287 B2 JP6300287 B2 JP 6300287B2
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- cells
- islet
- transplanted
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 252
- 229940125396 insulin Drugs 0.000 title claims description 127
- 102000004877 Insulin Human genes 0.000 title claims description 125
- 108090001061 Insulin Proteins 0.000 title claims description 125
- 210000004153 islets of langerhan Anatomy 0.000 title claims description 111
- 210000004027 cell Anatomy 0.000 claims description 104
- 238000002054 transplantation Methods 0.000 claims description 85
- 206010012601 diabetes mellitus Diseases 0.000 claims description 83
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 71
- 206010033675 panniculitis Diseases 0.000 claims description 61
- 229960004666 glucagon Drugs 0.000 claims description 52
- 102000051325 Glucagon Human genes 0.000 claims description 50
- 108060003199 Glucagon Proteins 0.000 claims description 50
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 29
- 210000004204 blood vessel Anatomy 0.000 claims description 19
- 210000001217 buttock Anatomy 0.000 claims description 19
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 13
- 230000000735 allogeneic effect Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 210000001015 abdomen Anatomy 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims 4
- 241000699670 Mus sp. Species 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 239000008103 glucose Substances 0.000 description 22
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 20
- 238000007920 subcutaneous administration Methods 0.000 description 20
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 18
- 229960001052 streptozocin Drugs 0.000 description 18
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
- 230000002950 deficient Effects 0.000 description 10
- 210000004304 subcutaneous tissue Anatomy 0.000 description 10
- 102100031250 Disks large-associated protein 1 Human genes 0.000 description 8
- 101000731000 Homo sapiens Membrane-associated progesterone receptor component 1 Proteins 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 210000003815 abdominal wall Anatomy 0.000 description 7
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 210000004013 groin Anatomy 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 210000003240 portal vein Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 101000911775 Mus musculus Hsc70-interacting protein Proteins 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
Description
(マウス)
オスのC57BL/6ならびにNOD/scidマウスはチャールス・リーバー・ジャパン社(日本神奈川県)から購入した。Jα18欠如(NKT細胞欠如)マウスは文献記載の方法で作製し(Cui, J., et al. Science 278, 1623-1626 (1997))、C57BL/6マウスに戻し交雑した。マウスは特定の無菌室で飼育し、8−16週齢で実験に使用した。全ての実験は福岡大学動物管理使用委員会の事前承認を受けたプロトコールに従って実施した。
膵島は文献記載の手法(Sutton, R., et al., Transplantation, 42, 689-691 (1986); Okeda, T., et al., Endocrinol. Jpn. 26, 495-499 (1979))に従って単離し、直径150−250μMのマウスを厳選して実験に供した。単離した膵島は、CO2培養器(5% CO2+95%空気)内で10%FBS添加培地(D−MEM、ニッスイ)を用いて24℃で1夜培養し、ドナーとして使用した。膵島は、STZ注射3日目に、STZ(Sigma)(180mg/kg)誘発糖尿病シンジェニツクレシピエントマウスの左側鼠蹊部皮下脂肪組織に移植した。非絶食状態の血漿グルコースレベルを、GlucoCard DIA meter (Arkray)を用いてSTZ注射の前後2回、膵島移植後は週に1回測定した。移植細胞の回収に当たっては、糖尿病レシピエントの膵島を含むポケットの閉口に使用したホッチキスの針をまず確認して、その針の基部と末端側を約5mmの長さに切除して以下の実験に使用した。比較のために、STZ誘発糖尿病レシピエントの肝臓内(Kemp., C. B., et al. Nature 244, 447 (1973))または腎臓被膜下(Yasunami, Y., et al., Transplantation 35, 281-284 (1983))に移植した。
膵島移植片を有する糖尿病レシピエントの切除した鼠蹊部皮下脂肪組織、肝臓ならびに腎臓は、10%ホルマリンで固定、加工、バラフィン包埋した後、形態分析のために切片にした。切片は、ヘマトキシリンとエオシンで染色し、免疫蛍光顕微鏡で観察した。使用した抗体は次の通りである:抗インスリン抗体、抗グルカゴン抗体、抗ソマトスタチン抗体ならびに抗PP抗体。染色した膵島移植切片は蛍光顕微鏡で観察した。
ヒト膵島は、Prodo Lab (Irvine, CA)から提供を受け、下記実験前2−3日間2%ヒトアルブミンを含むCMRL1066培地(Mediatech)中において24℃で培養した。
膵島移植後のSTZ誘発糖尿病マウスの正常血糖率についての統計分析は、Fisher's exact testによって決定した。p値が0.05未満である場合は有意差ありと判断した。
Claims (6)
- 1ドナーのインスリン産生膵島細胞数と略同数〜1/4の細胞数の同種又は異種由来インスリン産生膵島細胞を含む、栄養血管が広範囲に分布する鼠蹊部、腋下、背中、腹部から選択される少なくともいずれかの部位に存在する皮下脂肪組織へ移植してインスリン産生膵島細胞をNKT細胞活性抑制下にて生着させインスリン/グルカゴン同時陽性細胞を出現させるためのインスリン産生膵島細胞移植用製剤。
- 請求項1に記載のインスリン産生膵島細胞移植用製剤を収容してなる糖尿病レシピエントの皮下脂肪組織へ埋設し、皮下脂肪組織へ移植してインスリン産生膵島細胞をNKT細胞活性抑制下にて生着させるための移植用細胞含有容器。
- インスリン産生細胞を栄養血管が分布している非ヒト動物の鼠蹊部皮下脂肪組織に、NKT細胞活性抑制下にて、1ドナーの膵島細胞数と同数から1/4の割合の細胞数割合で移植することからなるインスリン産生細胞移植方法。
- 請求項3に記載のインスリン産生細胞移植方法であって、前記インスリン産生細胞が、ヒト膵島細胞、異種膵島細胞またはインスリン/グルカゴン同時陽性細胞であることからなるインスリン産生細胞移植方法。
- インスリン産生細胞を栄養血管が分布している非ヒト動物の鼠蹊部皮下脂肪組織に、NKT細胞活性抑制下にて、1ドナーの膵島細胞数と同数から1/4の割合の細胞数割合で移植し、移植インスリン産生細胞がインスリンを分泌し、分泌インスリンによって非ヒト動物の糖尿病を治療することからなる糖尿病治療方法。
- 請求項5に記載の糖尿病治療方法であって、前記インスリン産生細胞が、ヒト膵島細胞、異種膵島細胞またはインスリン/グルカゴン同時陽性細胞であることからなる糖尿病治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461979229P | 2014-04-14 | 2014-04-14 | |
US61/979,229 | 2014-04-14 | ||
PCT/JP2015/061492 WO2015159889A1 (ja) | 2014-04-14 | 2015-04-14 | インスリン産生細胞移植方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015159889A1 JPWO2015159889A1 (ja) | 2017-04-13 |
JP6300287B2 true JP6300287B2 (ja) | 2018-04-04 |
Family
ID=54324094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016513798A Active JP6300287B2 (ja) | 2014-04-14 | 2015-04-14 | インスリン産生膵島細胞移植用製剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6300287B2 (ja) |
WO (1) | WO2015159889A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2109085C (en) * | 1991-04-25 | 2003-03-11 | Keith E. Dionne | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
JP2001299908A (ja) * | 2000-04-26 | 2001-10-30 | Yasuhiko Tabata | 細胞移植用バッグ及び人工膵臓 |
US20120210451A1 (en) * | 2009-08-02 | 2012-08-16 | Hirofumi Shimizu | Islet cell sheet, process for production thereof, and use thereof |
-
2015
- 2015-04-14 WO PCT/JP2015/061492 patent/WO2015159889A1/ja active Application Filing
- 2015-04-14 JP JP2016513798A patent/JP6300287B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2015159889A1 (ja) | 2017-04-13 |
WO2015159889A1 (ja) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bottino et al. | The future of islet transplantation is now | |
Bruni et al. | Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges | |
Hering et al. | Current status of clinical islet transplantation | |
US20080318202A1 (en) | Chimeric pancreas | |
Prochorov et al. | Treatment of insulin dependent diabetes mellitus with intravascular transplantation of pancreatic islet cells without immunosuppressive therapy | |
Wszola et al. | Endoscopic islet autotransplantation into gastric submucosa—1000-day follow-up of patients | |
Poradzka et al. | Insulin replacement therapy in patients with type 1 diabetes by isolated pancreatic islet transplantation | |
ES2377464T3 (es) | Terapia celular: un método y una composición para tratar diabetes | |
JP5579270B2 (ja) | 膵島と脂肪組織由来幹細胞を利用した膵島移植 | |
Rajab et al. | Comparison of the portal vein and kidney subcapsule as sites for primate islet autotransplantation | |
Rabkin et al. | Transcontinental shipping of pancreatic islets for autotransplantation after total pancreatectomy | |
JP6300287B2 (ja) | インスリン産生膵島細胞移植用製剤 | |
US10507220B2 (en) | Cell therapy: a method and a composition for treating diabetes | |
Bertera et al. | Pig-to-macaque islet xenotransplantation | |
O'neil et al. | A simple and cost-effective method for the isolation of islets from nonhuman primates | |
Karl et al. | Transplantation of insulin-secreting tissues. | |
JP2019218273A (ja) | インスリン産生膵島細胞創生方法 | |
Mandel et al. | Effect of culture conditions on fetal mouse pancreas in vitro and after transplantation in syngeneic and allogeneic recipients | |
Peterson et al. | Human fetal pancreas transplants | |
CN109125348A (zh) | 脐带充质干细胞联合维生素d在治疗糖尿病药物中的应用 | |
Malasevskaia et al. | Stem Cells Therapy for Diabetes Mellitus Type 1. An Update on Safety and Outcomes | |
JP2008273842A (ja) | 移植片喪失の予防剤、及びそのスクリーニング方法 | |
Kinzer et al. | Pancreatic Islet Cells | |
Warnock | Frontiers in transplantation of insulin-secreting tissue for diabetes mellitus | |
Gull et al. | Artificial synthetic organs transplant: Prose and concerns in current scenario of modern and Arab world |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6300287 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |